Literature DB >> 10811688

Dopamine agonists: their role in the treatment of Parkinson's disease.

D J Brooks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10811688      PMCID： PMC1736955          DOI： 10.1136/jnnp.68.6.685

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  25 in total

1.  Risk of heart failure associated with dopamine agonists: a nested case-control study.

Authors:  P H Hsieh; F Y Hsiao
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

Review 2.  Nanoparticles in the brain: a potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases.

Authors:  Shermali Gunawardena
Journal:  Pharm Res       Date:  2013-04-27       Impact factor: 4.200

3.  L-type Ca2+ channel blockers promote Ca2+ accumulation when dopamine receptors are activated in striatal neurons.

Authors:  Molly E Eaton; Wendy Macías; Rachael M Youngs; Anjali Rajadhyaksha; Joshua T Dudman; Christine Konradi
Journal:  Brain Res Mol Brain Res       Date:  2004-11-24

4.  Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists.

Authors:  Stewart A. Factor
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

Review 5.  Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review.

Authors:  Nafsika Afentou; Johan Jarl; Ulf-G Gerdtham; Sanjib Saha
Journal:  Mov Disord Clin Pract       Date:  2019-04-11

6.  Dopamine Prevents Ultraviolet B-induced Development and Progression of Premalignant Cutaneous Lesions through its D2 Receptors.

Authors:  Kai Lu; Madhavi Bhat; Sara Peters; Rita Mitra; Xiaokui Mo; Tatiana M Oberyszyn; Partha Sarathi Dasgupta; Sujit Basu
Journal:  Cancer Prev Res (Phila)       Date:  2021-04-12

7.  Current approaches to the treatment of Parkinson's disease.

Authors:  Joseph Jankovic; L Giselle Aguilar
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

8.  Rhodococcus erythropolis MTHt3 biotransforms ergopeptines to lysergic acid.

Authors:  Michaela Thamhesl; Elisabeth Apfelthaler; Heidi Elisabeth Schwartz-Zimmermann; Elisavet Kunz-Vekiru; Rudolf Krska; Wolfgang Kneifel; Gerd Schatzmayr; Wulf-Dieter Moll
Journal:  BMC Microbiol       Date:  2015-03-28       Impact factor: 3.605

9.  Integrated dopaminergic neuronal model with reduced intracellular processes and inhibitory autoreceptors.

Authors:  Maell Cullen; KongFatt Wong-Lin
Journal:  IET Syst Biol       Date:  2015-12       Impact factor: 1.615

10.  Conserved role of dopamine in the modulation of behavior.

Authors:  Andrés G Vidal-Gadea; Jonathan T Pierce-Shimomura
Journal:  Commun Integr Biol       Date:  2012-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.